Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll […]
Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »
Nominations are now open for the 2014 Stem Cell Person of the Year Award. The winner receives $2,000 as well as recognition as a true difference maker and leader in the stem cell field. I found the first two years of this award process that all the finalists received a great deal of positive attention
Nominations Open for 2014 Stem Cell Person of the Year with $2,000 Prize Read More »
I believe in putting my money where my mouth is. When people in the stem cell field make extraordinary, positive contributions, they deserve major recognition and something tangible. With this goal in mind, I give out an annual Stem Cell Person of the Year Award. Past award winners have received the recognition and a $1,000
Stem Cell Person of the Year 2014 Award To Include $2,000 Prize Read More »
StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought
Interview with StemCells Inc. leadership on hot topics Read More »
The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung
Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »
Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here,
Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »
For the last month I’ve been accepting entries to my blog’s stem cell videos contest. This video contest follows up on other fund and educational contests I’ve run with prizes including a stem cell essay contest. In addition I do an annual Stem Cell Person of the Year Award with a $1,000 prize, which I personally pay
You’ve got to see these fun stem cell videos including contest winner Read More »
Many of this The Niche‘s readers ask about what my own lab’s research. What is the focus of the research of the Knoepfler Lab? You can go check out our lab website, but I thought it might be time to blog about what we are all about as a lab and what we have been
Knoepfler Lab: Our mission and research Read More »
Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it
Reflecting on Regenerative Medicine As A Brand Read More »
StemCells, Inc. is one of those stem cell-related biotech companies that we in the field hope will become a big success and help many patients in the future via stem cell technology. There are a lot of obstacles facing such companies. Some are privately held, while others such as StemCells, Inc. are publicly traded (stock
StemCells, Inc. Faces Lawsuit With Serious Allegations Read More »